UBP-302 is a highly selective Kainate receptor antagonist used in the study of many neurological processes. It is active at micromolar concentration within an in vitro preparation and specifically targets the GluR5 subunit of the receptor. This compound was developed at the University of Bristol.
This page contains content from the copyrighted Wikipedia article "UBP-302"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
